Business

Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase II Clinical Trial of GB08 for Injection

Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase II Clinical Trial of GB08 for Injection

articleKexing Biopharm Co., Ltd. Class ASeptember 2, 20253/news/announcement-on-voluntary-disclosure-of-completion-of-inclusion-of-the-first-subject-in-phase-ii-clinical-trial-of-gb08-for-injection
Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase II Clinical Trial of GB08 for Injection

About this update from Kexing Biopharm Co., Ltd. Class A

Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase II Clinical Trial of GB08 for InjectionThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Kexing Biopharm Co., Ltd. Class A